Biomaterial comprising poly(itaconate-co-citrate-co-octanediol)

Abstract

A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).

1 . A method of treating at least one of an infection or an inflammation in a subject, the method comprising:
 providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and   administering the polyester biomaterial to the subject.   
     
     
         2 . The method of  claim 1 , wherein the polyester biomaterial is in the form of a biomimetic. 
     
     
         3 . The method of  claim 1 , wherein the polyester biomaterial is characterized by hydrolytic degradability. 
     
     
         4 . The method of  claim 3 , wherein hydrolytic degradation of the polyester biomaterial causes release of therapeutic degradation products including itaconate. 
     
     
         5 . The method of  claim 4  wherein the degradation products include itaconate bonded with a diol monomer. 
     
     
         6 . The method of  claim 1 , wherein the polyester biomaterial is formed by polycondensation of the diol monomers with the itaconate monomers in the presence of a radical inhibitor. 
     
     
         7 . The method of  claim 1 , wherein the polyester biomaterial is formed by polycondensation in temperature range from ab out 120° C. to about 130° C. at atmospheric pressure. 
     
     
         8 . The method of  claim 1 , wherein the polyester biomaterial is formed by additional polycondensation at vacuum pressure. 
     
     
         9 . The method of  claim 1 , wherein the itaconate monomers comprise methylated itaconate. 
     
     
         10 . The method of  claim 1 , wherein the diol monomers are any one or a combination of 1,6-hexanediol, 1,8-octanediol and 1,10-decanediol. 
     
     
         11 . The method of  claim 1 , wherein the administering step comprises intraperitoneal injection. 
     
     
         12 . The method of  claim 1 , wherein the polyester biomaterial further comprises second carboxylate monomers. 
     
     
         13 . The method of  claim 12 , wherein the polyester biomaterial is formed by forming a polyester backbone including the diol and the second carboxylate monomers, and reacting with the polyester backbone with the itaconate monomers. 
     
     
         14 . The method of  claim 12 , wherein the polyester biomaterial is formed at atmospheric pressure at about 120° C. 
     
     
         15 . The method of  claim 12 , wherein the second carboxylate monomers comprise citrate. 
     
     
         16 . The method of  claim 1 , wherein the polyester biomaterial is provided as a scaffold before the administrating step. 
     
     
         17 . The method of  claim 16 , wherein the scaffold is for a tissue patch. 
     
     
         18 . A coating for a polymer surface or a metal surface, the coating comprising a polyester biomaterial comprising diol monomers and itaconate. 
     
     
         19 . The coating of  claim 18 , wherein the polymer surface or the metal surface is a surface of a medical device. 
     
     
         20 . A method of fabricating a polyester biomaterial comprising diol monomers and itaconate monomers, the method comprising:
 forming a polyester backbone including the diol monomers; and   reacting with polyester backbone with the itaconate monomers.